| Dry Eye Syndromes
Xiidra vs Lacrisert
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Xiidra vs Lacrisert with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLacrisert has a higher rate of injection site reactions vs Xiidra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lacrisert but not Xiidra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xiidra
Lacrisert
At A Glance
Ophthalmic
Twice daily
LFA-1 antagonist
Ophthalmic insert
Once daily
Ocular lubricant
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Exposure keratoconjunctivitis
- Corneal hypoesthesia
- Recurrent erosion of cornea
Dosing
Dry Eye Syndromes Instill one drop twice daily (approximately 12 hours apart) into each eye using a single-use container; remove contact lenses prior to administration and reinsert 15 minutes after.
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Exposure keratoconjunctivitis, Corneal hypoesthesia, Recurrent erosion of cornea One ophthalmic insert in each eye once daily; some patients may require twice daily use for optimal results; insert into the inferior cul-de-sac of the eye beneath the base of the tarsus.
Contraindications
- Known hypersensitivity to lifitegrast or any other ingredient in the formulation
- Hypersensitivity to hydroxypropyl cellulose
Adverse Reactions
Most common (>=5%) Instillation-site irritation, dysgeusia, reduced visual acuity
Common (1%-5%) Blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, sinusitis
Postmarketing Hypersensitivity reactions including anaphylactic reaction, bronchospasm, respiratory distress, pharyngeal edema, swollen tongue, urticaria, allergic conjunctivitis, dyspnea, angioedema, allergic dermatitis, eye swelling, rash
Most common Transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, hyperemia
Pharmacology
LFA-1 antagonist; lifitegrast binds to integrin LFA-1 on leukocytes, blocking its interaction with ICAM-1 and inhibiting T-cell adhesion and migration, thereby reducing inflammation in dry eye disease.
Ocular lubricant; stabilizes and thickens the precorneal tear film and prolongs tear film breakup time to reduce signs and symptoms of dry eye syndromes, including lubrication and protection of the eye.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xiidra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (11/12)
Lacrisert
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Xiidra
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Lacrisert
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Xiidra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Lacrisert
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Xiidra.
No savings programs available for Lacrisert.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XiidraView full Xiidra profile
LacrisertView full Lacrisert profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.